ETPrime

Sun Pharmaceutical Industries Share Price

  • 1,714.60-17.21 (-1.00%)
  • Volume: 9,92,672
  • Live
  • Last Updated On: 22 May, 2025, 12:30 PM IST
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Sun Pharmaceutical Industries Share Price
  • 1,714.60-17.21 (-1.00%)
  • Volume: 9,92,672
Advertisment

Sun Pharma Buy Or Sell?

Know what31 Analysts are recommending?

Expected Returns For Sun Pharma?

Discover this stock’sPotential Return & Target Price

Upside Potential by Sectors

Explore Upto95% Upside Potential in thePharmaceuticals Sector

Sun Pharma share price insights

View All

  • Meeting Agenda: Audited Results & Final Dividend. Please add to watchlist to track closely.

  • Company has spent less than 1% of its operating revenues towards interest expenses and 19.44% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

  • 200 day moving crossover appeared yesterday. Average price gain of 3.38% within 30 days of this signal in last 5 years.

  • 5 day moving crossover appeared yesterday. Average price gain of 2.55% within 7 days of this signal in last 5 years.

  • Sun Pharmaceutical Industries Ltd. share price moved down by -1.06% from its previous close of Rs 1,731.80. Sun Pharmaceutical Industries Ltd. stock last traded price is 1,713.60

    Share PriceValue
    Today/Current/Last1,713.60
    Previous Day1,731.801,731.60

InsightsSun Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		36.04
    EPS - TTM
    (₹)    		47.69
    MCap
    (₹ Cr.)    		4,13,045
    Sectoral MCap Rank
    		1
    PB Ratio
    (x)    		6.19
    Div Yield
    (%)    		0.79
    Face Value
    (₹)    		1.00
    Beta

    Beta

    1 Month0.00
    3 Months0.76
    6 Months0.92
    1 Year0.87
    3 Years0.92

    		0.00
    VWAP
    (₹)    		1,718.26
    52W H/L
    (₹)
    1,960.35 / 1,377.20

    Sun Pharma Share Price Returns

    1 Day-1.0%
    1 Week-1.47%
    1 Month-1.88%
    3 Months4.31%
    1 Year11.39%
    3 Years87.26%
    5 Years265.27%

    ET Stock ScreenersTop Score Companies

    Check whether Sun Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Sun Pharma News & Analysis

    View all Sun Pharma Share News & Announcements

    Sun Pharma Share Recommendations

    Recent Recos

    BUY

    Current

    Mean Recos by 31 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹1895
    • OrganizationICICI Securities
    • BUY
    • Target₹2115
    • OrganizationJM Financial
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy13131312
    Buy12121213
    Hold4446
    Sell2222
    Strong Sell----
    # Analysts31313133
    View all Stock Recommendations

    Sun Pharma Financials

    • Insights

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 19.44% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income14,141.0813,645.3913,185.3012,588.8412,630.90
      Total Income Growth (%)3.633.494.74-0.331.16
      Total Expenses10,613.179,978.349,700.269,699.759,595.82
      Total Expenses Growth (%)6.362.870.011.08-0.52
      EBIT3,527.913,667.053,485.042,889.093,035.08
      EBIT Growth (%)-3.795.2220.63-4.816.86
      Profit after Tax (PAT)2,912.983,040.162,835.622,654.582,523.75
      PAT Growth (%)-4.187.216.825.186.24
      EBIT Margin (%)24.9526.8726.4322.9524.03
      Net Profit Margin (%)20.6022.2821.5121.0919.98
      Basic EPS (₹)12.1012.7011.8011.1010.50
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income6,260.205,214.014,580.815,758.025,150.55
      Total Income Growth (%)20.0613.82-20.4411.79-1.00
      Total Expenses4,779.314,074.624,106.814,138.654,184.16
      Total Expenses Growth (%)17.29-0.78-0.77-1.091.99
      EBIT1,480.891,139.39474.001,619.37966.39
      EBIT Growth (%)29.97140.38-70.7367.57-12.16
      Profit after Tax (PAT)1,181.05863.29237.82867.60721.31
      PAT Growth (%)36.81263.00-72.5920.28-18.83
      EBIT Margin (%)23.6621.8510.3528.1218.76
      Net Profit Margin (%)18.8716.565.1915.0714.00
      Basic EPS (₹)4.903.601.003.603.00
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue49,851.0444,520.2039,576.0034,333.6633,473.48
      Total Revenue Growth (%)11.9712.4915.272.5711.24
      Total Expenses38,268.8334,940.3230,527.8627,228.1528,203.25
      Total Expenses Growth (%)9.5314.4512.12-3.4612.51
      Profit after Tax (PAT)9,576.388,473.583,272.732,903.823,764.93
      PAT Growth (%)13.01158.9112.70-22.8741.25
      Operating Profit Margin (%)24.3722.2223.7321.6316.97
      Net Profit Margin (%)19.7419.308.468.6611.46
      Basic EPS (₹)39.9035.3013.6012.1015.70
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue20,740.9321,091.1716,543.9012,953.4314,042.85
      Total Revenue Growth (%)-1.6627.4927.72-7.7621.32
      Total Expenses17,072.2616,412.3314,416.5110,711.0010,789.85
      Total Expenses Growth (%)4.0213.8434.60-0.7311.92
      Profit after Tax (PAT)2,858.181,690.72-99.992,139.703,211.14
      PAT Growth (%)69.05--104.67-33.37293.23
      Operating Profit Margin (%)21.9624.7516.1319.5229.21
      Net Profit Margin (%)14.098.12-0.6416.7125.62
      Basic EPS (₹)11.907.00-0.408.9213.40

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets85,462.8880,743.5969,799.8767,666.7368,252.46
      Total Assets Growth (%)5.8415.683.15-0.865.50
      Total Liabilities18,356.9121,428.1218,733.7618,186.9019,127.77
      Total Liabilities Growth (%)-14.3314.383.01-4.92-4.22
      Total Equity67,105.9759,315.4751,066.1149,479.8349,124.69
      Total Equity Growth (%)13.1316.153.210.729.84
      Current Ratio (x)2.562.002.041.892.02
      Total Debt to Equity (x)0.040.110.020.070.17
      Contingent Liabilities6,343.607,903.076,756.557,057.737,508.95
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets41,064.7940,987.4940,765.4838,998.8338,410.33
      Total Assets Growth (%)0.190.544.531.531.85
      Total Liabilities17,370.3917,239.1316,177.5313,958.6714,014.11
      Total Liabilities Growth (%)0.766.5615.90-0.40-5.76
      Total Equity23,694.4023,748.3624,587.9525,040.1624,396.22
      Total Equity Growth (%)-0.23-3.41-1.812.646.80
      Current Ratio (x)3.361.970.961.451.07
      Total Debt to Equity (x)0.470.320.200.260.24
      Contingent Liabilities2,013.744,309.603,811.823,564.253,863.62

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Decrease in Cash from Investing

        Company has used Rs 690.2 cr for investing activities which is an YoY decrease of 91.31%. (Source: Consolidated Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities12,134.984,959.338,984.546,170.376,554.77
      Net Cash used in Investing Activities-690.20-7,943.68-5,724.74536.22-2,588.84
      Net Cash flow from Financing Activities-6,710.162,376.07-5,193.46-5,980.48-5,715.14
      Net Cash Flow4,661.92115.48-1,764.78596.42-1,385.69
      Closing Cash & Cash Equivalent9,285.654,623.734,508.256,273.035,676.61
      Closing Cash & Cash Equivalent Growth (%)100.832.56-28.1310.51-19.62
      Total Debt/ CFO (x)0.231.250.100.541.16
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities-292.42507.087,636.361,737.251,305.85
      Net Cash used in Investing Activities-262.91-705.17-2,702.10-601.801,479.29
      Net Cash flow from Financing Activities473.95169.31-4,870.85-1,126.29-2,871.15
      Net Cash Flow-83.82-9.2568.471.84-82.26
      Closing Cash & Cash Equivalent326.46410.28419.53222.34220.50
      Closing Cash & Cash Equivalent Growth (%)-20.43-2.2088.690.83-27.17
      Total Debt/ CFO (x)-37.7814.970.643.734.40

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)15.0415.136.816.248.31
      Return on Capital Employed (%)17.2616.0217.4414.0610.60
      Return on Assets (%)11.2010.494.684.295.51
      Interest Coverage Ratio (x)60.2971.4088.8865.9525.19
      Asset Turnover Ratio (x)0.580.580.560.490.49
      Price to Earnings (x)40.6527.8667.1149.5022.47
      Price to Book (x)6.114.214.573.091.87
      EV/EBITDA (x)26.7519.5119.3015.3611.73
      EBITDA Margin (%)29.6427.9829.2827.8423.22
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)12.067.11-0.408.5413.16
      Return on Capital Employed (%)12.1515.798.208.1513.45
      Return on Assets (%)6.964.12-0.245.488.36
      Interest Coverage Ratio (x)7.7214.309.9612.0110.35
      Asset Turnover Ratio (x)0.490.510.390.330.33
      Price to Earnings (x)136.99140.85-2,500.0067.1126.32
      Price to Book (x)16.419.938.935.733.46
      EV/EBITDA (x)66.0036.0057.9048.4921.22
      EBITDA Margin (%)29.8532.4424.8024.1033.69

    Financial InsightsSun Pharma

    • Income (P&L)
    • Cash Flow

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 19.44% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

      • Decrease in Cash from Investing

        Company has used Rs 690.2 cr for investing activities which is an YoY decrease of 91.31%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Sun Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Sun Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Sun Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Sun Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Sun Pharma Technicals

    • Bullish / Bearish signals for Sun Pharma basis selected technical indicators and moving average crossovers.

      5 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 21 May 2025

      5D EMA: 1726.03

      Last 5 Buy Signals:15 May 2025
      Date7 days Gain/Loss %
      15 May 20250.09%
      11 Apr 20254.17%
      3 Apr 20250.50%
      6 Mar 20254.53%
      27 Feb 20251.43%

      Average price gain of 2.55% within 7 days of Bullish signal in last 5 years

      200 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 21 May 2025

      200D EMA: 1713.46

      Last 4 Buy Signals:15 May 2025
      Date30 days Gain/Loss %
      15 May 20250.09%
      17 Apr 20255.69%
      15 Apr 2025-0.13%
      2 Apr 20255.78%

      Average price gain of 3.38% within 30 days of Bullish signal in last 5 years

      Show More
    • 47%
      Positive Movement since
      1st Jan 2005 on basis
      53%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic1734.131752.571783.571721.571703.131690.571659.57

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR41.9045.2645.33

    Sun Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Sun Pharma36.066.1515.0417.2611.2013.1024.3719.8939.902.560.040.23
          Divis Labs78.8611.5414.6318.8512.932.2731.1723.4082.536.940.000.00
          Cipla22.633.8116.9021.5714.108.7324.9819.2065.294.250.000.02
          Torrent Pharma57.3514.4425.1728.7012.749.7525.6016.5956.471.190.401.17
          Dr. Reddys18.103.0216.8521.8111.4415.1124.3217.4764.221.920.120.90
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Mankind Pharma
          • Cadila Healthcare
          • Lupin
          • Aurobindo Pharma
          • Alkem Labs

          Choose from Stocks

            See All Parameters

          Peers InsightsSun Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Sun Pharma Shareholding Pattern

            • Loading...
              Showing Sun Pharma Shareholding as on Mar 2025
              CategoryMar 2025Dec 2024Sep 2024Jun 2024
              Promoters54.4854.4854.4854.48
              Pledge0.880.690.791.07
              FII17.9518.0418.0017.23
              DII18.4818.3518.4119.08
              Mutual Funds12.2112.2412.1112.78
              Others9.099.129.119.21
            • Showing Shareholding as on Mar 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters1,30,71,34,53554.48 %0.00
              Pledge1,14,65,4000.88 %0.19
              FII43,08,62,93417.95 %-0.08
              DII44,34,98,63718.48 %0.12
              MF29,30,51,62012.21 %-0.02
              Others21,78,38,8649.09 %-0.03

            Sun Pharma MF Ownership

            MF Ownership as on 30 April 2025

            View all Mutual Fund Schemes
            Top Searches:
            Sun Pharma News Sun Pharma Quarterly Results Sun Pharma Dividend Sun Pharma Q1 ResultsSun Pharma Q2 ResultsSun Pharma Q3 ResultsSun Pharma Q4 Results

            Sun Pharma F&O Quote

              • Expiry

              Price

              1,724.00-12.00 (-0.69%)

              Open Interest

              1,61,17,1502,66,750 (1.68%)

              OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
              1,738.101,743.101,713.401,736.0094217,846.47

              Open Interest as of 22 May 2025

              • Type
              • Expiry
              • Strike Price

              Price

              30.75-8.50 (-21.66%)

              Open Interest

              5,71,90061,600 (12.07%)

              OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
              42.9543.1527.5039.2569513,399.50

              Open Interest as of 22 May 2025

            Sun Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              May 22, 2025May 12, 2025Board MeetingAudited Results & Final Dividend
              Mar 27, 2025Feb 20, 2025POM-
              Jan 31, 2025Jan 16, 2025Board MeetingQuarterly Results & Interim Dividend
              Jan 21, 2025Dec 10, 2024COM-
              Oct 28, 2024Oct 09, 2024Board MeetingQuarterly Results
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Interim1050%10.5Feb 06, 2025Jan 16, 2025
              Final500%5.0Jul 12, 2024May 22, 2024
              Interim850%8.5Feb 09, 2024Jan 15, 2024
              Final400%4.0Jul 28, 2023Jul 07, 2023
              Interim750%7.5Feb 08, 2023Jan 16, 2023
            • All TypesEx-DateRecord DateAnnounced onDetails
              BonusJul 29, 2013Jul 30, 2013May 28, 2013Bonus Ratio: 1 share(s) for every 1 shares held
              SplitsNov 25, 2010Nov 26, 2010Sep 24, 2010Split: Old FV5.0| New FV:1.0
              BonusMay 27, 2004May 29, 2004Apr 21, 2004Bonus Ratio: 1 share(s) for every 1 shares held
              SplitsJan 13, 2003Jan 21, 2003Oct 28, 2002Split: Old FV10.0| New FV:5.0
              BonusMar 06, 2000Mar 23, 2000Feb 09, 2000Bonus Ratio: 2 share(s) for every 1 shares held

            About Sun Pharma

            Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 4,15,516.83 Crore) operating in Pharmaceuticals sector. Sun Pharmaceutical Industries Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2024. Show More

            • Executives

            • Auditors

            • DS

              Dilip S Shanghvi

              Chairman & Managing Director
              AG

              Abhay Gandhi

              CEO - North America
              SD

              S Damodharan

              CEO - API Business
              UB

              Uday Baldota

              CEO - Taro Pharmaceutical Industries Ltd.
              AD

              Aalok D Shanghvi

              Whole Time Director
              SV

              Sudhir V Valia

              Non Exe.Non Ind.Director
              Show More
            • S R B C & Co. LLP

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty 50, BSE Sensex, Nifty 100, + 48 more

            Address

            Sun Pharma Advanced Research Centre (SPARC),Tandalja,Vadodra, Gujarat - 390012

            Contact

            [email protected]

            http://www.sunpharma.com

            More Details

            Brands

            Sun Pharma
            Revital
            Show More

            FAQs about Sun Pharma share

            • 1. What's Sun Pharma share price today and what are Sun Pharma share returns ?
              Sun Pharma share price is Rs 1,718.90 as on 22 May, 2025, 12:10 PM IST. Sun Pharma share price is down by 0.75% based on previous share price of Rs 1,707.8. Sun Pharma share price trend:
              • Last 1 Month: Sun Pharma share price moved down by 1.63%
              • Last 3 Months: Sun Pharma share price moved up by 4.57%
              • Last 12 Months: Sun Pharma share price moved up 11.67%
              • Last 3 Years: Sun Pharma Share price moved up by 87.72%
            • 2. What are the key metrics to analyse Sun Pharma Share Price?
              Sun Pharma share can be quickly analyzed on following metrics:
              • Stock's PE is 36.09
              • Price to Book Ratio of 6.19
            • 3. What is the market cap of Sun Pharma?
              Within the Pharmaceuticals sector, Sun Pharma stock has a market cap rank of 1. Sun Pharma has a market cap of Rs 4,14,029 Cr.
            • 4. Who are the key owners of Sun Pharma stock?
                • Promoter holding has not changed in last 9 months and holds 54.48 stake as on 31 Mar 2025
                • Domestic Institutional Investors holding have gone down from 19.08 (30 Jun 2024) to 18.48 (31 Mar 2025)
                • Foreign Institutional Investors holding has gone up from 17.23 (30 Jun 2024) to 17.95 (31 Mar 2025)
                • Other investor holding have gone down from 9.21 (30 Jun 2024) to 9.09 (31 Mar 2025)
            • 5. What are the returns for Sun Pharma share?
              Return Performance of Sun Pharma Shares:
              • 1 Week: Sun Pharma share price moved down by 1.22%
              • 1 Month: Sun Pharma share price moved down by 1.63%
              • 3 Month: Sun Pharma share price moved up by 4.57%
              • 6 Month: Sun Pharma share price moved down by 4.26%
            • 6. What is the CAGR of Sun Pharma?
              The CAGR of Sun Pharma is 9.69.
            • 7. Which are the key peers to Sun Pharma?
              Top 10 Peers for Sun Pharma are Divi's Laboratories Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mankind Pharma Ltd., Zydus Lifesciences Ltd., Lupin Ltd., Aurobindo Pharma Ltd., Alkem Laboratories Ltd. and Biocon Ltd.
            • 8. What has been highest price of Sun Pharma share in last 52 weeks?
              In last 52 weeks Sun Pharma share had a high price of Rs 1,960.35 and low price of Rs 1,377.20
            • 9. Who is the Chief Executive Officer of Sun Pharma?
              Abhay Gandhi is the CEO - North America of Sun Pharma
            • 10. What are the Sun Pharma quarterly results?
              Total Revenue and Earning for Sun Pharma for the year ending 2024-03-31 was Rs 49851.04 Cr and Rs 9576.38 Cr on Consolidated basis. Last Quarter 2024-12-31, Sun Pharma reported an income of Rs 14141.08 Cr and profit of Rs 2912.98 Cr.
            • 11. What is the PE & PB ratio of Sun Pharma?
              The PE ratio of Sun Pharma stands at 36.31, while the PB ratio is 6.19.
            • 12. What dividend is Sun Pharma giving?
              An equity Interim dividend of Rs 10.5 per share was declared by Sun Pharmaceutical Industries Ltd. on 16 Jan 2025. So, company has declared a dividend of 1050% on face value of Rs 1 per share. The ex dividend date was 06 Feb 2025.

            Trending in Markets

            Top Gainers As on 12:26 PM | 22 May 2025

            Tata Teleservices78.59
            9.50 (13.76%)
            Fortis Healthcare734.95
            62.91 (9.36%)
            SCI195.80
            14.00 (7.71%)
            GRSE2,656.90
            156.41 (6.26%)
            Craftsman Automation5,585.20
            286.50 (5.41%)

            Top Losers As on 12:24 PM | 22 May 2025

            Aditya Birla Retail89.90
            -179.05 (-66.58%)
            Colgate-Palmolive2,533.20
            -126.11 (-4.75%)
            Redington276.92
            -12.96 (-4.48%)
            Mankind Pharma2,440.00
            -91.41 (-3.62%)
            BSE7,042.00
            -263.00 (-3.61%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Sun Pharma Share Price
            The Economic Times
            BrowseCompanies:
            OSZAR »